$PALI Income Statement | Understand Stock

$PALI

$1.20 -$0.03 (2.44%) Close

Financial Statements

In millions of USD; shares in millions, except per-share amounts

	FY2025 12 months to Dec 31, 2025	FY2024 12 months to Dec 31, 2024	FY2023 12 months to Dec 31, 2023	FY2022 12 months to Dec 31, 2022	FY2021 12 months to Dec 31, 2021
Operating expenses:
License revenue
Research and development
In-process research and development
General and administrative
Restructuring costs (Note 8)
Total operating expenses
Loss from operations

Other (expense) income:
Gain on forgiveness of PPP loan
Loss on issuance of secured debt
Gain on change in fair value of warrant liability
Gain on change in fair value of share liability
Interest expense
Other income, net
Loss on issuance of Leading Biosciences, Inc. Series 1 Preferred Stock
Loss on issuance of warrants

Total other income, net
Net loss
Net loss available to common stockholders - basic
Net loss attributable to common shares - diluted
Weighted average shares used in computing (loss) income per common share:
Basic weighted average shares used in computing net loss per common share
Diluted weighted average shares used in computing net loss per common share
(Loss) income per common share:
Basic net loss per common share
Diluted net loss per common share

Comments